(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
‘Nahariya get ready’: Banner displaying Hezbollah threat mounted in Tehran’s Palestine Square- 6 Well known Ladies' Fragrances On the planet
- 7 Powerful Methods for forestalling Telephone Overheating: Keep Your Gadget Cool
- Orcas seen hunting great white sharks to eat their livers in drone footage recorded in Mexico
- Last supermoon of the year, the cold moon, seen across the U.S.: See the photos
- Instructions to Upgrade the Mechanical Highlights of Your Shrewd Bed for a Superior Night's Rest
- Reclassifying Achievement: Individual Accounts of Seeking after Interests
- Make your choice for the PS5 game that you love playing with companions!
- Ariana Grande says Eternal Sunshine 2026 tour will be her last for a 'long, long time': 'One last hurrah'
